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Objective: Stem cells offer great potential for clinical therapeutic use because of their ability to rejuve-
nate and to differentiate into numerous types of cells. We isolated multipotent cells from the human
term placenta that were capable of differentiation into cells of all three germ layers.
Materials and methods: We examined the ability of these placenta-derived multipotent cells (PDMCs) to
differentiate into osteoblasts (OBs) or OB-like cells. The PDMCs were treated with osteogenic medium
(OM) consisting of dexamethasone, b-glycerol phosphate, and ascorbic acid. At sequential time intervals
(0 day, 3 days, 6 days, 9 days, and 12 days) we measured several parameters. These included alkaline
phosphatase (ALP) activity, alizarin red staining (ARS) to measure calcium deposition, messenger RNA
(mRNA) expressions of osteogenesis-related transcription factor (Cbfa1), and calcium coordination
protein (osteocalcin). These variables were used as indicators of PDMC osteodifferentiation.
Results: We showed that ALP activity in the early stage of differentiation and calcium deposition were
both signiﬁcantly increased in PDMCs after OM induction. Moreover, the Cbfa1 and osteocalcin gene
expressions were upregulated. The results suggested that OM induced an osteodifferentiation potential
in PDMCs.
Conclusion: PDMC-derived osteocytes provide a useful model to evaluate the mechanisms of key bio-
molecules and bioengineering processes.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
The plasticity of adult stem cells has led to the hope that these
versatile cells might offer therapeutic potential in a range of ap-
plications [1,2]. Two crucial factors that determine the ability of
stem cells to differentiate are the nature of the stem (progenitor)
cell itself and the microenvironment in which it resides [3].
Numerous studies have focused on the effects of biological mole-
cules (e.g., growth factors, cytokines, drugs, and small molecules)h Institute, Cathay General
jhih, Taipei 22174, Taiwan.
.
bstetrics & Gynecology. Publishedon this differentiation process. However, researchers now recog-
nize that inorganic or tissue-engineered materials may also criti-
cally affect the fate of cells [4,5].
Bones are formed from the cellular component known as the
osteoblast (OB) and its progenitor, the bone marrow mesenchymal
stem cell (BMMSC). Bone formation is affected by the microenvi-
ronment and certain biomaterials [6,7]. Although bone tissue is
capable of regeneration after injury, the quality of healing varies;
inadequate healing might result in limited function and a poor
outcome [8]. Osteoporosis (OP) is a bone disease in which bone
resorption by osteoclasts (OCs) exceeds the bone formation by OBs
[9]. In elderly women, decreased estrogen levels lead to an imbal-
ance in this bone remodeling unit comprising OB and OC [10].by Elsevier Taiwan LLC. All rights reserved.
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fractures of the spine or hip joint, with an increase in the associated
morbidity and mortality [11].
Current treatment of OP focuses either on decreasing OC activity
or increasing OB activity. OC activity may be increased through
treatment with bisphosphonates or estrogen and related com-
pounds [12e14], whereas OB activity may be increased with
parathyroid hormone or calcitonin [15]. However, bones remain
brittle in OP patients, and the use of standard agents to assist in the
healing of fractures is insufﬁcient. The addition of cellular compo-
nents, namely OBs and its progenitors, may be necessary as an
adjuvant to improve the patient's outcome [16]. However, OBs and
MSCs do not occur abundantly and are accessed by invasive pro-
cedures. We thus investigated a possible alternative source of
suitable cells.
We isolated a population of multipotent cells from the human
term placenta that were capable of differentiating into cells of all
three germ layers [17]. Placenta-derived multipotent cells (PDMCs)
occur in abundance and can be obtained without invasive pro-
cedures. Furthermore, the immunosuppressive properties of
PDMCs render them ideal candidates for therapeutic applications
[18,19]. We monitored the process of osteogenesis induced from
PDMCs. We used multiple molecular markers to identify and track
the osteogenic differentiation of these PDMCs.
Materials and methods
Isolation and ex vivo expansion of PDMCs
Term placentas (at 38e40 weeks' gestation) were obtained from
healthy donormothers who gave their informed consent, according
to the procedure outlined by our institutional review board
(approval number CT 9870). We collected 20 term-pregnancy pla-
centas during the study period. The cells were isolated as previ-
ously reported [17]. Brieﬂy, placental tissue was dissected after
drainage of the umbilical cord blood. Mechanical and enzymatic
treatment was applied, and then the homogenate was cultured in
basal medium (BM) consisting of Dulbecco's modiﬁed Eagle's me-
dium (Gibco-Invitrogen, Grand Island, NE, USA) supplemented by
10% fetal bovine serum (FBS; selected lots; HyClone, Logan, UT,
USA), 100 U/mL penicillin, and 100 U/mL streptomycin (Sigma-
Aldrich, St. Louis, MO, USA). Cell cultures were maintained at 37C
with a water-saturated atmosphere and 5% CO2. The culture me-
dium was replaced once or twice per week.
Phenotypic characterization of PDMCs
Immunophenotyping was performed using ﬂow cytometry with
a FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA) controlled
by CellQuest software (BD Biosciences). Cells were detached with
trypsin/EDTA, washed, and resuspended in phosphate-buffered
saline (PBS) with 1% FBS. For the detection of intracellular anti-
gens, cells were additionally permeabilized with 70% ethanol for 10
minutes at 4C. The cells (1  105/mL) were then stained on ice for
30 minutes with saturating amounts of monoclonal antibodies
conjugated by ﬂuorescein isothiocyanate (FITC) or by phycoery-
thrin (PE). Antibodies recognizing the following human antigens
were used: human leucocyte antigen-DR (HLA-DR; Class II, 1:50),
CD9 (1:50), CD34 (1:50), CD44 (1:50), CD45 (1:50), CD73 (1:50),
and CD90 (1:50). These antibodies were purchased from BD Bio-
sciences. We also used CD49e (1:50), CD54 (1:50), CD105 (1:50),
and hStro-1 (1:25) antibodies, which were purchased from Milli-
pore/Chemicon (Temecula, CA, USA); CD13 (1:50), CD14 (1:50), and
CD29 (1:50) obtained from Biolegend (San Diego, CA, USA); and
HLA-ABC (Class I, 1:50) and CD166 (1:5) purchased fromAbDSerotec (Raleigh, NC, USA). Unconjugated anti-SH3 (1:5) and
anti-SH4 (1:5) monoclonal antibodies were developed in-house,
and FITC-conjugated rat antimouse immunoglobulin G (BD Bio-
sciences) was used as the secondary antibody.
Osteoblastic differentiation
Cells were seeded in six-well plates at a density of 3  105 cells
per well in BM to promote cell growth. Differentiationwas achieved
by culturing cells in OM, which comprised BM and 0.1 mM dexa-
methasone (Sigma-Aldrich), 10 mM b-glycerol phosphate (Sigma-
Aldrich), and 50 mm ascorbate (Sigma-Aldrich). The medium was
changed every 3 days and induction was preceded for 12 days.
Alkaline phosphatase activity assay
Cells were seeded and cultured in BM. After the indicated time
had elapsed for culturing, the cell layers were rinsed with PBS,
scraped into an 0.5 mL buffer solution (10 mM TriseHCl, pH 7.0;
Sigma-Aldrich), sonicated four times to disrupt the cells on ice, and
centrifuged (4000g) at 4C for 15 minutes. The supernatant was
collected and used for the alkaline phosphatase (ALP) assay. ALP
activity was determined using an ALP substrate kit (Bio-Rad Lab-
oratories, Hercules, CA, USA). Absorbance at 405 nmwas measured
with a spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).
ALP activity was calibrated by protein amount, determined using a
Bradford Protein Assay kit (Bio-Rad Laboratories).
Alizarin red staining
Alizarin red staining (ARS) for calcium depositionwas assayed as
previously described [19]. The PDMCs were ﬁrst treated with OM
for the indicated number of days. At the indicated time point, the
medium was discarded and the cells were washed with PBS twice;
thereafter, 70% ethanol was added to ﬁx the cells at 4C for 1 hour.
The cells were then washed with PBS twice. The staining solution
(40 mM Alizarin Red S, pH 4.2; Sigma-Aldrich) was added and
incubated with rotation at room temperature for 5 minutes. Finally,
the staining solution was aspirated and the cells were washed with
distilled water three times. The staining images were visualized
using a Nikon Eclipse 80i (Nikon, Tokyo, Japan) and captured by
Q Capture Pro software (QImaging, Surrey, BC, Canada, version
5.1.1.14).
Quantitative reverse-transcriptase polymerase chain reaction
Total RNA was extracted from the cultured cells using TRIzol
(Invitrogen, Carlsbad, CA, USA). The messenger RNA (mRNA) was
reverse transcribed to complementary DNA (cDNA) using a Super-
Script III First-Strand Synthesis System (Invitrogen) according to the
manufacturer's instructions. The cDNAwas converted using random
hexmers with Superscript III Reverse Transcriptase (RT) under the
following conditions: 25C for 10minutes, 50C for 50minutes, 85C
for 5 minutes, 37C for 20 minutes, and ﬁnally 72C for 10 minutes.
The quantitative (q) polymerase chain reaction (PCR) was per-
formed using Roche Lightcycler and Master Mix (Roche Applied
Science, Mannheim, Germany) primers designed for the corre-
sponding human genes. The sequences of these primers for humans
are as follows: osteocalcin forward primer 50-TGAGAGCCCTCA-
CACTCCTC-30; reverse primer: 50-ACCTTTGCTGGACTCTGCAC-30;
Cbfa1 forward primer 50-GTGCCTAGGCGCATTTCA-30; reverse
primer: 50-GCTCTTCTTACTGAGAGTGGAAGG-30; GAPDH forward
primer 50-CTCTGCTCCTCCTGTTCGAC-30; reverse primer: 50-
ACGACCAAATCCGTTGACTC-30. The qRT-PCR was performed as fol-
lows: pre-incubation at 95C for 10 minutes; 60 cycles of
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seconds, and ﬁnally 40C for 30 seconds.
Results
Immunophenotype of human PDMCs
PDMCs were isolated from human placentas at term in vitro. The
immunophenotype of the PDMCs was analyzed by ﬂow cytometry
(Fig. 1). The results showed that the undifferentiated cells were
negative for HLA-DR, CD34, CD45 (hematopoietic surface markers),
and hStro1. However, the PDMCs were positive for CD9, CD13,
CD14, CD29, CD44, CD54, CD73, CD90, CD105, CD166, HLA-ABC,
SH3, and SH4. These markers were generally positive in the
BMMSCs [2].
Osteogenic differentiation
The morphology of PDMCs was similar to that of the BMMSCs
[Fig. 2, left (untreated)]. The PDMCswere then treatedwith OM and
allowed to incubate for 12 days, during which timewe observed the
morphological changes in osteodifferentiation in the PDMCs
(Fig. 2). The morphology of induced PDMCs became rough and
some precipitant was evident under the optical microscope at 9
days, compared with untreated cells. ARS was performed to furtherFig. 1. Immunophenotype of placenta-derived multipotent cells (PDMCs). Fluorescence-act
indicates the background signal, and the shaded histogram indicates positive reactivity.characterize the calcium deposition of induced PDMCs. ARS-
positive cells were detected 9 days after OM treatment; the stain-
ing became obvious on Day 12, indicating massive calcium aggre-
gation (Fig. 2, Day 12 treated with OM). These ﬁndings provide
direct evidence of bone formation or osteogenesis after OM
treatment.
Treatment with OM-induced alkaline phosphatase activity in
PDMCs
Osteogenic stimulation of PDMCs was identiﬁed by measuring
ALP activity, which is considered an early indication of osteogenesis
in BMMHCs [20,21]. We investigated the ALP kinetics in PDMCs
during the 12 days incubation after OM treatment. After OM was
added to the cell culture, ALP activity began to be detected and
increased gradually. The induced PDMCs showed a signiﬁcant in-
crease in ALP activity over time, reaching a peak at Day 9 and
declining from the peak at Day 12 (Fig. 3). This result showed that
ALP activity was induced at the early stage of PDMC differentiation
into osteocytes.
Characterization of differentiated PDMCs
To conﬁrm that osteogenesis was induced by OM in PDMCs,
we performed qRT-PCR analysis to evaluate the mRNA expressionivated cell sorting analysis was performed after the ﬁfth passage. The open histogram
Fig. 2. The cell morphology and alizarin red staining (ARS) of placenta-derived multipotent cells (PDMCs) and differentiated osteoblasts (OBs). PDMCs were treated with osteogenic
medium (OM) and harvested at speciﬁc time intervals. Osteogenesis was conﬁrmed by ARS (scale bar ¼ 100 mm).
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is an osteogenesis-related protein that interacts with Ca2þ to
form an osteoscaffold [22], whereas Cbfa1 is an essential tran-
scription factor in osteogenesis [23]. Cbfa1 binds to and regulates
the expression of multiple genes expressed in OBs and is regar-
ded as an essential transcription factor for bone formation
[24,25]. The mRNA expression of osteocalcin showed a steady
increase over time, with the expression on Day 12 being four-fold
that of Day 1 (Fig. 4A). Cbfa1 also showed a steady increase in
mRNA expression, although the slope was milder than for
osteocalcin (Fig. 4B). By monitoring the molecular markers
related to osteogenesis, we identiﬁed the osteogenic progress
induced by OM in PDMCs.Discussion
Stem cells offer great potential for clinical applications because of
their properties of self-renewal and the ability to differentiate into
various cell types [1,2]. However, the current sources of stem cells are
beset by ethical and biological limitations. We thus isolated a pop-
ulation of multipotent cells from the human term placenta, which
were capable of differentiation into cells of all three germ layers,
including an osteoblastic phenotype [17]. Compared with other
sources of multipotent cells, placental cells are less problematic
ethically and are widely available. PDMCs occur abundantly and can
be obtained without invasive procedures, unlike BMMSCs. Several
types of nonhematopoietic stem cells, including embryonic stem
Fig. 3. Analysis of alkaline phosphatase (ALP) activity. ALP activity quantiﬁcation was
repeated every 3 days for 12 days after the initial treatment with osteogenic medium
(OM). The proteins at each time point were extracted and analyzed from three inde-
pendent preparations. The p value in the ALP analysis was less than 0.05.
Fig. 4. Quantiﬁcation of osteogenic-related gene expression in placenta-derived
multipotent cells (PDMCs) by quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR). Quantiﬁcation of the gene expression levels of (A) osteocalcin and
(B) Cbfa1 were repeated every 3 days for 12 days after treatment with osteogenic
medium (OM). The messenger RNA (mRNA) at each time point was extracted and qRT-
PCR of each gene was analyzed from three independent cell culture preparations. The p
value of osteocalcin gene expression was less than 0.05.
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properties. We previously reported that PDMCs possess signiﬁcant
immunosuppressive properties [18]; thus these cells should be
considered candidates for future therapeutic applications.
In this study, we showed that osteoblastic differentiation was
achieved by culturing PDMCs in OM. The OM consisted of basal
mediumwith 0.1 mMdexamethasone, 10 mM b-glycerol phosphate,
and 50 mm ascorbate. Various evaluations of enzymatic and mo-
lecular markers of osteogenesis were performed, including ALP
assay, ARS, and qRT-PCR to quantify osteocalcin and Cbfa1 mRNA
expressions. ARS was used to identify calcium formation during
osteogenesis, because calcium forms an Alizarin Red Secalcium
complex in a chelating process [26]. Calcium deposition indicates
the possible osteodifferentiation derived in PDMCs. As shown in
Fig. 2, the cells displayed signiﬁcant ARS positivity on Day 12. The
enzymatic activity of ALP was detected during the early stages of
osteogenesis in cells treatedwith OM, and gradually increased until
Day 9, when the ALP level was 3.4-fold compared with Day 1. The
ALP activity decreased from Day 9 to Day 12, showing that ALP
provides a marker in the early stages.
We also quantiﬁed the mRNA expression levels of two
osteogenic-related genes: Cbfa1 and osteocalcin. Cbfa1 is an
important factor for maintaining bone homeostasis and a key
mediator in controlling osteoblastic cell differentiation [25]. As
shown in Fig. 4B, the level of Cbfa1 ﬁrst increased, and then slightly
decreased from approximately Day 6, then steadily increased again.
Osteocalcin is a bone marker associated with osteogenesis, and
plays an important role in bone remodeling and production [27,28].
Osteocalcin is a negatively charged (pI ¼ 4.0) small protein that is
capable of forming a tightly-packed charged molecule coordinated
with Ca2þ at the surface of the lattice of bone mineral crystals [29].
Our ﬁndings identiﬁed the occurrence of osteogenesis, as shown by
osteocalcin mRNA expression and quantiﬁcation (Fig. 4A). On Day
12, a signiﬁcant increase in osteocalcin gene expression (indicating
osteogenic differentiation) was noted, with the osteocalcin level
having increased signiﬁcantly to four-fold compared with Day 1.
OP is a disease of the bone in which bone resorption by OCs
exceeds bone formation by OBs [9]. The number of elderly women
who sustain OP-related fractures has reached epidemic proportions
[10]. Recent studies have shown that OP can be treated either by
decreasing OC activity with bisphosphonates or estrogen and
estrogen-related compounds [9e11] or by increasing OB activity
with parathyroid hormone or calcitonin [12]. A decrease in OC ac-
tivity helps to maintain bonemass and skeletal integrity. Sources of
OB are limited in OP patients and the use of standard agents to heal
bone fractures may not be sufﬁcient. The use of stem cells as an
adjuvant source to replenish OBs should thus be considered [13].
However, MSCs do not occur in natural abundance and require
invasive procedures to obtain. PDMCs constitute an ethically un-
problematic and abundant source of multipotent cells, which are
capable of multilineage differentiation and possess immunosup-
pressive properties. Thus, PDMCs may provide an easily available
in vitromodel for OP. The therapeutic potential of PDMCs in treating
OP should be further investigated.
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